Mr Brendan Reardon

PhD Student
eHealth Hub For Cancer
GDI
Graduate Student (jointly with Prof Eli Van Allen, DFCI)
twitter GitHub LinkedIn Homepage email

Mr Brendan Reardon

Brendan Reardon’s research focuses on developing algorithms for the clinical interpretation of individual patient molecular data for precision oncology.

Publications

Full list of publications see Google Scholar

Recent publications include

[1] J. R. Conway, R. Gillani, J. Crowdis, et al. "Somatic structural
variants drive distinct modes of oncogenesis in melanoma". Eng. In:
_The Journal of clinical investigation_ 134.13 (May. 2024). ISSN:
1558-8238. DOI: 10.1172/JCI177270. PMID: 38758740.
[2] C. Gurjao, J. Cazaubiel, C. Tan, et al. "Germline predisposition to
oncogenic alkylating damage in colorectal cancer". Eng. In: _medRxiv :
the preprint server for health sciences_ (Jul. 2025). DOI:
10.1101/2025.06.30.25330572. PMID: 40630591.
[3] C. Gurjao, J. Cazaubiel, C. Tan, et al. "Germline predisposition to
oncogenic alkylating damage in colorectal cancer". Eng. In: _Cancer
epidemiology, biomarkers & prevention : a publication of the American
Association for Cancer Research, cosponsored by the American Society of
Preventive Oncology_ (Dec. 2025). ISSN: 1538-7755. DOI:
10.1158/1055-9965.EPI-25-1006. PMID: 41416871.
[4] C. Gurjao, R. Zhong, K. Haruki, et al. "Discovery and Features of
an Alkylating Signature in Colorectal Cancer". Eng. In: _Cancer
discovery_ 11.10 (Oct. 2021), pp. 2446-2455. ISSN: 2159-8290. DOI:
10.1158/2159-8290.CD-20-1656. PMID: 34140290.
[5] S. H. Han, S. Y. Camp, H. Chu, et al. "Integrative Analysis of
Germline Rare Variants in Clear and Non-clear Cell Renal Cell
Carcinoma". Eng. In: _European urology open science_ 62 (Apr. 2024),
pp. 107-122. ISSN: 2666-1683. DOI: 10.1016/j.euros.2024.02.006. PMID:
38496821.
[6] S. Han, S. Y. Camp, H. Chu, et al. "Integrative Analysis of
Germline Rare Variants in Clear and Non-Clear Cell Renal Cell
Carcinoma". Eng. In: _medRxiv : the preprint server for health
sciences_ (Jan. 2023). DOI: 10.1101/2023.01.18.23284664. PMID:
36712083.
[7] B. M. Huffman, H. Singh, L. R. Ali, et al. "Biomarkers of
pembrolizumab efficacy in advanced anal squamous cell carcinoma:
analysis of a phase II clinical trial and a cohort of long-term
responders". Eng. In: _Journal for immunotherapy of cancer_ 12.1 (Jan.
2024). ISSN: 2051-1426. DOI: 10.1136/jitc-2023-008436. PMID: 38272561.
[8] H. Jun, Y. Tanaka, S. Johri, et al. "A context-augmented large
language model for accurate precision oncology medicine
recommendations". Eng. In: _Cancer cell_ (Jan. 2026). ISSN: 1878-3686.
DOI: 10.1016/j.ccell.2025.12.017. PMID: 41544626.
[9] H. Jun, Y. Tanaka, S. Johri, et al. "Implementing a
context-augmented large language model to guide precision cancer
medicine". Eng. In: _medRxiv : the preprint server for health sciences_
(Jul. 2025). DOI: 10.1101/2025.05.09.25327312. PMID: 40778147.
[10] T. E. Keenan, J. L. Guerriero, R. Barroso-Sousa, et al. "Molecular
correlates of response to eribulin and pembrolizumab in hormone
receptor-positive metastatic breast cancer". Eng. In: _Nature
communications_ 12.1 (Sep. 2021), p. 5563. ISSN: 2041-1723. DOI:
10.1038/s41467-021-25769-z. PMID: 34548479.
[11] N. R. Mahadevan, E. H. Knelson, J. O. Wolff, et al. "Intrinsic
Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular
Plasticity". Eng. In: _Cancer discovery_ 11.8 (Aug. 2021), pp.
1952-1969. ISSN: 2159-8290. DOI: 10.1158/2159-8290.CD-20-0913. PMID:
33707236.
[12] M. Mossanen, F. L. F. Carvalho, V. Muralidhar, et al. "Genomic
Features of Muscle-invasive Bladder Cancer Arising After Prostate
Radiotherapy". Eng. In: _European urology_ 81.5 (May. 2022), pp.
466-473. ISSN: 1873-7560. DOI: 10.1016/j.eururo.2021.12.004. PMID:
34953602.
[13] B. Reardon, A. C. Culhane, and E. M. Van Allen. "Convergence of
machine learning and genomics for precision oncology". Eng. In: _Nature
reviews. Cancer_ (Jan. 2026). ISSN: 1474-1768. DOI:
10.1038/s41568-025-00897-6. PMID: 41478861.
[14] B. Reardon, N. D. Moore, N. S. Moore, et al. "Integrating
molecular profiles into clinical frameworks through the Molecular
Oncology Almanac to prospectively guide precision oncology". Eng. In:
_Nature cancer_ 2.10 (Oct. 2021), pp. 1102-1112. ISSN: 2662-1347. DOI:
10.1038/s43018-021-00243-3. PMID: 35121878.
[15] J. Schiantarelli, T. Pappa, J. Conway, et al. "Mutational
Footprint of Platinum Chemotherapy in a Secondary Thyroid Cancer". Eng.
In: _JCO precision oncology_ 6 (Aug. 2022), p. e2200183. ISSN:
2473-4284. DOI: 10.1200/PO.22.00183. PMID: 36075011.
[16] K. Sehgal, T. Pappa, K. Shin, et al. "Dual Immune Checkpoint
Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2
Nonrandomized Clinical Trial". Eng. In: _JAMA oncology_ 10.12 (Dec.
2024), pp. 1663-1671. ISSN: 2374-2445. DOI:
10.1001/jamaoncol.2024.4019. PMID: 39446365.
[17] M. Shady, B. Reardon, S. Jiang, et al. "Learning Patient
Similarity from Genomics for Precision Oncology". Eng. In: _medRxiv :
the preprint server for health sciences_ (Dec. 2025). DOI:
10.64898/2025.12.17.25342480. PMID: 41445600.
[18] G. Tarantino, C. A. Ricker, A. Wang, et al. "Genomic heterogeneity
and ploidy identify patients with intrinsic resistance to PD-1 blockade
in metastatic melanoma". Eng. In: _Science advances_ 10.48 (Nov. 2024),
p. eadp4670. ISSN: 2375-2548. DOI: 10.1126/sciadv.adp4670. PMID:
39602539.
[19] D. Van Egeren, K. Kohli, J. L. Warner, et al. "Genomic analysis of
early-stage lung cancer reveals a role for TP53 mutations in distant
metastasis". Eng. In: _Scientific reports_ 12.1 (Nov. 2022), p. 19055.
ISSN: 2045-2322. DOI: 10.1038/s41598-022-21448-1. PMID: 36351964.
[20] A. G. Waks, J. Fu, X. Chu, et al. "Efficacy, safety, and
predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab
in hormone receptor-positive breast cancer: A randomized pilot trial".
Eng. In: _Nature communications_ 16.1 (Nov. 2025), p. 10705. ISSN:
2041-1723. DOI: 10.1038/s41467-025-66667-y. PMID: 41315271.